Diabetes Clinical Trial
Official title:
Racial/Ethnic Differences in Trust/Mistrust and Its Effect on Diabetes Outcomes
1. Determine racial/ethnic differences in trust in physicians and mistrust of the health
care system among veterans with Type 2 Diabetes.
2. Determine the predictive power of trust in physicians and mistrust of the health care
system on personal health practices and health outcomes in a prospective cohort of
veterans with Type 2 Diabetes
Background/Significance: Diabetes mellitus is a chronic and progressive disease that causes
significant morbidity and mortality and increases health care utilization and costs in both
Veteran Administration (VA) and non-VA settings. 1. Diabetes and its complications are more
prevalent in minority populations. Black Americans have two-fold increased age adjusted
rates of diabetes, are more likely to develop and experience greater disability from
diabetes complications compared to White Americans. 1. Black Americans with diabetes have
higher rates of retinopathy, end-stage renal disease, lower limb amputations, and overall
death rates. 2. Therefore, diabetes is a significant public health problem and Black
American patients have disproportionately higher morbidity and mortality than their White
American counterparts.
Several factors have been postulated to explain the disproportionately higher morbidity and
mortality from diabetes in Black Americans and these include their mistrust of the health
care system. 3. It is thought that distrustful patients are less likely to seek routine
medical care, take prescribed medications consistently, adhere to treatments
recommendations, and maintain continuity with health care providers and health care systems.
4. Recent studies show that Black Americans are less trusting of physicians and the health
care system. 5. However, little is known about the association between trust and diabetes
outcomes and whether distrust of physicians and the health care system contributes to the
observed racial/ethnic differences in diabetes outcomes.
Theoretical Framework: The conceptual and theoretical framework of this study is the revised
behavioral model of health services use (Andersen 1974, 1968, 1983, 1995). The model posits
that people's use of health services is a function of their predisposition to use services,
factors that enable or impede use, and their need for care (Andersen 1995). Trust in
physicians and the health system falls under health beliefs (attitudes toward health
services), which is one of the predisposing factors that is thought to predict health
services utilization and health outcomes. Thus, people with high levels of trust in
physicians and the health care system are expected to have more effective access,
appropriate health utilization, and better health outcomes. The model has been revised to
include veteran-specific variables such as level of service entitlement, period of service,
duration in the VA system, and disability status and to measure both health services use and
health outcomes.
Research Design and Methods: This is a prospective cohort study with five hypotheses
organized under their specific aims as follows:
Specific Aim #1: Determine racial/ethnic differences in trust in physicians and mistrust of
the health care system among veterans with Type 2 Diabetes.
Hypothesis #1: There is a difference in mean scores on the general trust in physician scale
(GTIPS) between White and Black American veterans with Type 2 diabetes.
Hypothesis #2: There is a difference in mean scores on the Health Care System Distrust Scale
between White and Black American veterans with Type 2 diabetes.
Specific Aim #2: Determine the predictive power of trust in physicians and mistrust of the
health care system on personal health practices and health outcomes in a prospective cohort
of veterans with Type 2 Diabetes
Hypothesis #1: Controlling for predisposing, enabling, need, and veteran-specific factors,
diabetic veterans with lower trust scores or higher mistrust scores will be less likely to
keep office appointments, take prescribed medications, and adhere to diabetes
self-management recommendations after 12 months of follow-up.
Hypothesis #2: Controlling for predisposing, enabling, need, and veteran-specific factors,
diabetic veterans with lower trust scores or higher mistrust scores will have higher mean
hemoglobin A1C, blood pressure, and LDL cholesterol levels after 12 months of follow-up.
Hypothesis #3: Controlling for predisposing, enabling, need, and veteran-specific factors,
diabetic veterans with lower trust scores or higher mistrust scores will be less likely to
accept influenza vaccination after 12 months of follow-up.
Study site & Subjects: Patients will be recruited from the Charleston VAMC. Equal number of
White and Black American veterans aged 18 years and older with Type 2 Diabetes will be
recruited. Race/ethnicity will be based on self-report. The diagnosis of type 2 Diabetes as
well as health utilization and diabetes-specific health outcomes will be obtained from the
VA electronic medical records system (CPRS). There are approximately 6,961 patients with
Type 2 Diabetes at this site, of which 49.1% (3,417) are White Americans, 31.5% (2,189) are
Black Americans, and 19.4% (1,355) are Hispanic or other. Approximately 97.5% are men and
90% are aged 50 years or older.
Sample size calculation:
Specific Aim #1: Sample Power V2.0 (SPSS) was used for sample size calculation based on the
convention outlined by Cohen6. Overall experiment wise error was held to ?=0.05, and power
to 80% using medium (0.25) effect sizes. Correction for multiplicity of tests (2 tests for
primary hypotheses) involved using ?=0.025 (0.05/2). This yielded 125 patients per group. In
addition, the sample was inflated to account for an estimated 20% attrition at 1 year of
follow-up (death, relocation, or loss to follow-up). No more than 150 eligible patients need
to be enrolled per group. Thus, 300 patients (150 Whites and 150 African Americans) will be
recruited.
Specific Aim #2: The sample size determination for a reliable regression equation offered by
Stevens7 is 15 subjects per predictor variable. Using this standard, a sample size of 300,
as determined above, would allow the inclusion of 20 predictor variables. Because none of
the hypotheses for Specific Aim 2 exceed 20 predictor variables, a sample of 300 will be
adequate.
Survey Instruments: The GTIPS4 is a valid and reliable 11-item measure of general trust in
physicians and the Health Care System Distrust Scale is a valid and reliable 10-item measure
of mistrust of the health care system. Both instruments have been validated in Black and
White Americans.
Statistical Analysis Plan: Descriptive statistics will be used to describe the
characteristics of participants in the study.
Specific Aim #1: Mean scores on the trust and mistrust scales at baseline will be compared
between White and Black Americans with the two-sample t-test and similar comparisons will be
made while controlling for covariates (predisposing, enabling, need, and veteran-specific
factors) using Analysis of Covariance (ANCOVA).
Specific Aim #2: Multiple linear regression will be used to test the effect of mean
trust/mistrust scores on health utilization and mean hemoglobin A1C, blood pressure, and LDL
cholesterol after 12 months of follow-up controlling for covariates. Similarly, multiple
logistic regression will be used to test the effect of trust/mistrust on acceptance of the
influenza vaccine controlling for covariates. STATA V8.0 will be used for data analysis and
all tests will be two-tailed with overall p=0.05 for each hypothesis.
;
Observational Model: Cohort, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
| Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
| Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
| Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
| Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
| Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
| Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
| Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
| Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
| Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
| Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
| Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |